Full-Time
Associate Director
Scientific Communications
Compass Pathways
201-500 employees
Develops psilocybin-based therapies for TRD
Compensation Overview
$210k - $255k/yr
No H1B Sponsorship
Remote in USA
Remote
PharmD, PhD, MD
 Biology & Biotech |
|---|
Get referred to Compass Pathways
See people who can refer or advise you
- An advanced scientific degree (PharmD, PhD, MD, DO, PsyD, or equivalent) in a relevant scientific discipline is required.
- At least 8 years of experience in Medical Affairs, Scientific Communications, Publications, or a related function within the biopharmaceutical industry and/or a scientific or medical communications agency is required.
- Demonstrated experience leading publication planning and execution, including manuscripts, abstracts, posters, and scientific presentations, is required.
- Experience supporting scientific communications for major medical congresses is required.
- Exceptional scientific writing, editing, and communication skills are required, including the ability to translate complex data into clear and compelling scientific communications.
- The candidate must be highly collaborative and able to maintain the confidence to make decisions and move work forward.
- Drive defined Scientific Communications plans within Medical Affairs and contribute to scalable processes and capabilities supporting launch and long-term growth.
- Partner with Medical Affairs leadership to develop and execute an integrated Scientific Communications strategy aligned with organizational priorities.
- Identify opportunities to improve scientific information communication through thoughtful, innovative approaches that enhance clarity, quality, and impact.
- Select and manage vendors and engage external thought leader collaborators.
- Lead publication planning and execution across the Medical Affairs portfolio to ensure timely and effective dissemination of scientific evidence.
- Refine and continuously improve publication planning processes, governance, and execution with cross-functional stakeholders.
- Partner with internal subject matter experts, Clinical Development, and external authors to develop manuscripts, abstracts, posters, and oral presentations in accordance with compliance policies.
- Monitor publication timelines and proactively identify risks, opportunities, and dependencies.
- Lead scientific planning for key medical congresses in partnership with cross-functional teams.
- Coordinate congress scientific communications with publication plans and organizational priorities.
- Support development of abstracts, posters, presentations, and related scientific content.
- Ensure congress activities maximize scientific engagement and effective dissemination of new evidence.
- Collaborate with the Field Medical organization to develop high-quality scientific communications supporting scientific exchange.
- Develop and maintain scientific slide decks, FAQs, educational resources, advisory board materials, presentations, and other Medical Affairs communications.
- Translate complex scientific and clinical data into accurate, engaging communications tailored to diverse scientific audiences.
- Ensure scientific consistency across Medical Affairs communications through review and content stewardship.
- Own and continuously evolve the Treatment-Resistant Depression Scientific Communications Platform as the scientific foundation for Medical Affairs communications.
- Partner with internal scientific leaders to develop and maintain the PTSD Scientific Communications Platform.
- Integrate emerging scientific evidence into communication platforms and core Medical Affairs materials.
- Prior leadership experience in Scientific Communications with demonstrated success managing multiple priorities in a fast-paced environment.
- Experience in psychiatry, neuroscience, or other central nervous system therapeutic areas.
- Launch or pre-commercial experience.
- Intellectual curiosity and enjoyment of solving complex scientific and operational challenges.
COMPASS Pathways develops psilocybin-based therapies for mental health, focusing on treating treatment-resistant depression (TRD). Its lead drug candidate, COMP360, is a high-purity psilocybin formulation given alongside psychological support from trained therapists. The treatment is delivered through a global Phase 3 program, aiming to establish a regulatory-approved therapy. Compared with other players, COMPASS emphasizes a standardized therapeutic model that pairs a pharmaceutical compound with guided psychotherapy and has the largest psilocybin Phase 3 program to date, supported by Breakthrough Therapy designation from the FDA. The company originated from a nonprofit idea, transformed into a for-profit entity to fund extensive trials, and is pursuing regulatory approval and eventual commercialization through licensing and partnerships. Its goal is to bring approved, evidence-based psilocybin treatments to patients with TRD and scale access through a commercial pathway.
Company Size
201-500
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
2016
Get referred to Compass Pathways
See people who can refer or advise you
Simplify's Take
What believers are saying
- Compass reported $433.3 million cash on June 30, 2026, funding into 2028.
- FDA granted rolling NDA review and a National Priority Voucher in April 2026.
- Positive COMP006 data and VA collaboration strengthen launch credibility before first-half 2027.
What critics are saying
- FDA rejection of the Q4 2026 NDA ends the 2027 launch and crushes Compass.
- DEA rescheduling delays block commercialization even after FDA approval, pushing revenue past 2027.
- Commercial adoption needs therapists, clinics, and payer coverage; weak reimbursement caps uptake.
What makes Compass Pathways unique
- COMP360 is the first classic psychedelic with positive Phase 3 TRD data, July 2026.
- Compass owns proprietary synthetic psilocybin and FDA Breakthrough Therapy designation for COMP360.
- The VA PIVOT trial with veterans expands Compass into a uniquely credible federal channel.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Hybrid Work Options
Company Equity
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -6%2 year growth
↓ -6%Compass Pathways recognized as a 2026 Fierce 50 Breakthrough honoree. September 2, 2026 · Logan Lenz COMPASS Pathways Plc (CMPS) - LONDON & NEW YORK, September 02, 2026-Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare.
Compass Pathways shares rose over 6% on Monday, contributing to a 25% gain in August, as the company prepares to complete its FDA application for COMP360, a synthetic psilocybin treatment for treatment-resistant depression. The firm expects to finish the full submission in the fourth quarter of this year, with a potential launch in the first half of 2027 if approved. The FDA previously granted COMP360 a special priority voucher, which could reduce the final review period to just one or two months. In early August, Compass reported a cash position of $433 million as of June, sufficient to fund operations into 2028. Two large late-stage studies demonstrated COMP360's quick-acting, long-lasting benefits. The company is also advancing a late-stage PTSD study whilst building commercial capabilities.
Compass Pathways working with U.S. Department of veterans Affairs for investigational study of psilocybin. August 6, 2026 · Logan Lenz COMPASS Pathways Plc (CMPS) - LONDON & NEW YORK, August 06, 2026-Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumat
Compass Pathways to participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026. LONDON & NEW YORK-(BUSINESS WIRE)- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, and will participate in a fireside chat at 8:00am ET. Management will also participate in the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026. A live audio webcast of this event will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways NovumPR believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Its initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. NovumPR is leading the world's largest classic psychedelic clinical program in TRD, and building upon that robust foundation, NovumPR is executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Its goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing. Compass is headquartered in London, UK, with a U.S. office in New Jersey. NovumPR is driven by its purpose of unlocking pathways to be - opening futures filled with possibility. Together, NovumPR is on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass.
Compass Pathways announced second quarter and first half 2026 financial results as it progresses towards potential FDA approval of COMP360, its synthetic psilocybin treatment for treatment-resistant depression. The company reported cash and cash equivalents of $433.3 million as of 30 June 2026, up from $149.6 million at year-end 2025. Net loss was $162.6 million for the first half, compared with $56.3 million in the same period of 2025, primarily due to non-cash warrant fair value adjustments. Compass completed a rolling NDA submission to the FDA and expects to finalise remaining modules in Q4 2026. The company received a National Priority Voucher that could accelerate review time to one to two months. Commercial launch is expected in first half 2027, subject to FDA approval and DEA rescheduling. Current cash position is projected to fund operations into 2028.